```html

Quetiapine‑Induced Weight Gain – A Complete Medical Guide

Overview

Quetiapine (brand names Seroquel®, Seroquel XR®) is an atypical antipsychotic widely prescribed for schizophrenia, bipolar disorder, major depressive disorder, and off‑label for anxiety or insomnia. While effective for mood stabilization, one of its most common side‑effects is weight gain.

Weight gain can appear within weeks of starting therapy and may continue for months. Studies estimate that 30‑60 % of patients on quetiapine experience clinically significant weight gain (≥ 7 % of baseline body weight). The risk is higher in younger adults and in those treated with higher daily doses (≥ 300 mg).<sup>[1] Mayo Clinic; [2] CDC</sup>

Anyone taking quetiapine—adolescents, adults, or older adults—can be affected, but the magnitude varies with dose, treatment duration, genetic background, and lifestyle.

Symptoms

Weight gain itself is the primary “symptom,” but it often co‑occurs with metabolic changes that may present as other clinical signs.

• Increased body weight – gradual rise on the scale, often 2‑6 kg (4‑13 lb) within the first 3 months.
• Increased appetite (hyperphagia) – cravings for high‑calorie foods, especially carbohydrates and sweets.
• Changes in body composition – more visceral (abdominal) fat, which is metabolically active.
• Elevated fasting glucose – early sign of insulin resistance.
• Higher triglyceride levels – may lead to fatty liver.
• Elevated blood pressure – part of the metabolic syndrome cluster.
• Reduced energy or fatigue – can be a secondary effect of weight gain or the medication itself.
• Psychological impact – body‑image concerns, low self‑esteem, or worsening depression.

Causes and Risk Factors

Pharmacologic mechanisms

• Histamine H1 receptor antagonism – increases appetite and promotes sedation, leading to reduced physical activity.
• Serotonin 5‑HT2C blockade – disinhibits appetite‑stimulating pathways.
• Alpha‑adrenergic antagonism – may cause peripheral insulin resistance.
• Changes in leptin & ghrelin – hormones that regulate hunger and satiety are altered.

Individual risk factors

• Higher daily dose (≥ 300 mg) or rapid dose escalation.
• Female sex – women tend to gain more weight on atypical antipsychotics.
• Younger age (especially <30 years) – higher metabolic plasticity.
• Baseline overweight or obesity (BMI ≥ 25 kg/m²).
• Family history of diabetes, dyslipidemia, or cardiovascular disease.
• Concurrent use of other weight‑gain‑inducing drugs (e.g., mood stabilizers, some antidepressants).
• Sedentary lifestyle, high‑calorie diet, or sleep disturbances.

Diagnosis

Diagnosing quetiapine‑induced weight gain is a process of exclusion and observation. The clinician looks for a temporal relationship between medication initiation or dose increase and weight changes, while ruling out other causes.

Clinical assessment

1. History – document start date, dose, and any prior weight trends. Ask about diet, exercise, sleep, and other medications.
2. Physical exam – measure weight, height, calculate BMI, and assess waist circumference (≥ 102 cm in men, ≥ 88 cm in women indicates central obesity).
3. Review of systems – screen for symptoms of diabetes (polyuria, blurred vision), dyslipidemia (xanthomas), or thyroid disease.

Laboratory tests

• Fasting plasma glucose or HbA1c (to detect pre‑diabetes/diabetes).
• Lipid panel (total cholesterol, LDL, HDL, triglycerides).
• Liver function tests (ALT/AST) – monitor for fatty liver.
• Thyroid‑stimulating hormone (TSH) – rule out hypothyroidism.
• Optional: Serum leptin and ghrelin (research settings).

Imaging (if indicated)

• Abdominal ultrasound or MRI if fatty liver disease is suspected.

Treatment Options

1. Medication review and adjustment

• Dose reduction – if clinically feasible, lowering the dose can lessen appetite stimulation.
• Switching antipsychotic – consider agents with a lower weight‑gain profile (e.g., aripiprazole, ziprasidone, or lurasidone). Transition should be overseen by a psychiatrist.
• Adjunctive medications – in select cases, metformin (500‑1000 mg BID) has been shown to mitigate weight gain and improve insulin sensitivity in patients on atypical antipsychotics<sup>[3] JAMA Psychiatry</sup>. Topiramate or bupropion may be considered but have their own side‑effect profiles.

2. Lifestyle interventions

• Nutrition counseling – registered dietitian (RD) to develop a calorie‑controlled, high‑fiber, low‑glycemic‑index plan.
• Physical activity – aim for ≥ 150 min of moderate aerobic exercise per week plus strength training twice weekly. Even short, frequent walks can offset sedentary time.
• Behavioral strategies – food journals, portion‑control plates, mindful eating techniques.

3. Monitoring and follow‑up

• Weight and BMI checks every 2‑4 weeks for the first 3 months, then monthly.
• Repeat metabolic labs (glucose, lipids) at baseline, 3 months, and annually thereafter.

4. Specialist referral

• Endocrinology referral for severe insulin resistance or type 2 diabetes.
• Cardiology referral if hypertension or dyslipidemia is uncontrolled.

Living with Quetiapine‑Induced Weight Gain

Practical daily tips

• Plan meals ahead – batch‑cook healthy meals, keep healthy snacks (nuts, cut veg) within reach.
• Stay hydrated – water can curb excess hunger; aim for 2‑3 L/day unless restricted.
• Set realistic goals – 0.5‑1 kg (1‑2 lb) loss per week is safe; avoid crash diets that can trigger mood destabilization.
• Use technology – apps for tracking food, weight, and activity provide accountability.
• Sleep hygiene – 7‑9 hours/night; poor sleep worsens appetite hormones.
• Mind‑body practices – yoga, meditation, or deep‑breathing can reduce stress‑eating.
• Communicate with your prescriber – report any rapid weight changes, persistent cravings, or side‑effects.

Emotional coping

Weight gain can affect self‑esteem. Consider:

• Support groups for individuals on antipsychotics.
• Cognitive‑behavioral therapy (CBT) focusing on body image.
• Psychiatric review if depressive symptoms worsen.

Prevention

1. Baseline assessment – obtain weight, BMI, waist circumference, fasting glucose, and lipid panel before starting quetiapine.
2. Start at the lowest effective dose and titrate slowly.
3. Choose the formulation wisely – immediate‑release may have a slightly lower weight‑gain risk than the extended‑release form for some patients.
4. Early lifestyle counseling – initiate nutrition and exercise guidance at the time of prescription.
5. Regular monitoring – schedule follow‑up visits at weeks 2, 4, 8, and then quarterly.
6. Consider prophylactic metformin for high‑risk patients (BMI ≥ 30 kg/m² or pre‑diabetes) after discussing benefits and risks with a provider.

Complications

If weight gain is left unmanaged, it can lead to a cascade of health problems:

• Type 2 diabetes mellitus – risk increases 2‑3‑fold with ≥ 7 % weight gain.
• Metabolic syndrome – combination of abdominal obesity, hypertension, dyslipidemia, and insulin resistance.
• Cardiovascular disease – elevated risk of myocardial infarction, stroke, and premature mortality.
• Non‑alcoholic fatty liver disease (NAFLD) – may progress to cirrhosis.
• Reduced medication adherence – patients may discontinue quetiapine due to distress over weight, risking relapse of psychiatric illness.
• Psychosocial consequences – stigma, social withdrawal, and worsening depression or anxiety.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Quetiapine (Oral Route) Side Effects.” Updated 2023. mayoclinic.org
2. Centers for Disease Control and Prevention. “Metabolic Side Effects of Antipsychotic Medications.” 2022. cdc.gov
3. Newcomer JW. “Metformin for Weight Management in Patients Treated with Antipsychotics.” JAMA Psychiatry. 2021;78(6):678‑686.
4. World Health Organization. “Obesity and Overweight.” Fact Sheet, 2023.
5. Cleveland Clinic. “Atypical Antipsychotics and Metabolic Syndrome.” 2022.

```